Geron Corporation Reaches Profitability in Q3 2026 Driven by Rytelo Sales
Geron (GERN) shares rose over 10% in premarket trading following the company's announcement of its first profitable quarter in years. The Q3 2026 results were characterized by significant top-line growth, marking a major financial turning point for the biotech firm. The profitability was primarily driven by strong commercial performance of Rytelo, the company's blood cancer therapy. This shift from consistent quarterly losses to positive earnings reflects the successful market adoption and scaling of its primary therapeutic product.
Tickers: $GERN
Topics: biotech earnings profitability stock price movement
Read the full article at Seeking Alpha
Part of the story Geron Corp Reports Third Quarter 2026 Profitability Driven by RYTELO Growth (15 articles)